In this randomized , double-blind , phase 3 study , patients ( N = 342 ) received canagliflozin 100 or 300mg during a 26-week , placebo-controlled , core period and a 26-week , active-controlled extension in which placebo-treated patients were switched to sitagliptin 100mg .